Body composition is prognostic and predictive of ipilimumab activity in metastatic melanoma

BACKGROUND: Body composition is minimally investigated in an immunotherapy era. Specific body composition signals such as myosteatosis may reflect aspects of patients' immunology and thereby their ability to respond to immunotherapies. Ipilimumab is a key checkpoint inhibitor in metastatic mela...

Descripción completa

Detalles Bibliográficos
Autores principales: Chu, Michael P., Li, Yuetong, Ghosh, Sunita, Sass, Shelley, Smylie, Michael, Walker, John, Sawyer, Michael B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7296257/
https://www.ncbi.nlm.nih.gov/pubmed/32053287
http://dx.doi.org/10.1002/jcsm.12538

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7296257/
https://www.ncbi.nlm.nih.gov/pubmed/32053287
http://dx.doi.org/10.1002/jcsm.12538

Ejemplares similares